Compare PK & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | AMLX |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2014 | 2021 |
| Metric | PK | AMLX |
|---|---|---|
| Price | $11.10 | $17.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $11.10 | ★ $20.11 |
| AVG Volume (30 Days) | ★ 3.4M | 1.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.82% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,791,000,000.00 | $380,786,000.00 |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.35 | ★ 1612.94 |
| 52 Week Low | $9.51 | $4.41 |
| 52 Week High | $12.39 | $17.49 |
| Indicator | PK | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 68.37 |
| Support Level | $10.07 | $13.19 |
| Resistance Level | $11.77 | N/A |
| Average True Range (ATR) | 0.31 | 0.91 |
| MACD | 0.10 | 0.28 |
| Stochastic Oscillator | 68.63 | 97.08 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.